





This listing of claims will replace all prior versions, and listings, of claims in the application:




**Listing of Claims:**

1. (Original) A compound of Formulas I, II, III, or IV:



wherein

- A is an indazolyl, benzothiazolyl, or isobenzothiazolyl group according to subformulas (a) to (c), respectively,



X is O or S;

R<sup>1</sup> is H, F, Cl, Br, I, OH, CN, nitro, NH<sub>2</sub>, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

R<sup>2</sup> is H, alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, or cycloalkylalkyl having 4 to 7 carbon atoms;

R<sup>3</sup> is H, F, Cl, Br, I, OH, CN, nitro, NH<sub>2</sub>, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

R<sup>4</sup> is H, F, Cl, Br, I, OH, CN, nitro, NH<sub>2</sub>, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group

independently has 1 to 4 carbon atoms, Ar or Het;

R<sup>5</sup> is H, F, Cl, Br, I, OH, CN, nitro, NH<sub>2</sub>, alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, cycloalkylalkoxy having 4 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

Ar is an aryl group containing 6 to 10 carbon atoms which is unsubstituted or substituted one or more times by alkyl having 1 to 8 C atoms, alkoxy having 1 to 8 C atoms, halogen, dialkylamino wherein the alkyl portions each have 1 to 8 C atoms, amino, cyano, hydroxyl, nitro, halogenated alkyl having 1 to 8 C atoms, halogenated alkoxy having 1 to 8 C atoms, hydroxyalkyl having 1 to 8 C atoms, hydroxyalkoxy having 2 to 8 C atoms, alkenyloxy having 3 to 8 C atoms, alkylthio having 1 to 8 C atoms, alkylsulphinyl having 1 to 8 C atoms, alkylsulphonyl having 1 to 8 C atoms, monoalkylamino having 1 to 8 C atoms, cycloalkylamino wherein the cycloalkyl group has 3 to 7 C atoms and is optionally substituted, aryloxy wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, arylthio wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, cycloalkyloxy wherein the cycloalkyl group has 3 to 7 C atoms and is optionally substituted, sulfo, sulfonylamino, acylamido, acyloxy or combinations thereof; and






Het is a heterocyclic group, which is fully saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl having 6 to 10 carbon atoms and is optionally substituted, alkyl having 1 to 8 C atoms, alkoxy having 1


to 8 C atoms, cyano, trifluoromethyl, nitro, oxo, amino, monoalkylamino having 1 to 8 C atoms, dialkylamino wherein each alkyl group has 1 to 8 C atoms, or combinations thereof; or

a pharmaceutically acceptable salt thereof,


wherein when said compound is of Formula I the indazolyl group of group A is attached via its 3, 4, or 7 position, the benzothiazolyl group of group A is attached via its 4 or 7 position, or the isobenzothiazolyl group of group A is attached via its 3, 4, or 7 position.

2. (Original) A compound according to claim 1, wherein said compound is of formulas Ia, Ib, Ie, If, Ii, Ij, Ik, or Io:






(Ij)




(Ik)




(Io)


3. (Original) A compound according to claim 1, wherein said compound is of formula IIa to IIo:




(IIa)




(IIb)




(IIc)




(IIId)




(IIe)




(IIIf)




(IIg)




(IIh)




(Ili)





(IIj)






(IIk)




(IIIm)




4. (Original) A compound according to claim 1, wherein said compound is of formula IIIa to IIIo:







(IIIId)




(IIIle)




(IIIIf)




(IIIlg)




(IIIh)




(IIIli)



(IIIj)




(IIIk)




(IIIIm)




5. (Original) A compound according to claim 1, wherein said compound is of formula IVa to IVo:




(IIIIn)




(IIIlo)




(IVa)




(IVb)




(IVc)




(IVd)




(IVe)




(IVf)




(IVg)




(IVh)




(IVi)




(IVj)




(IVk)



(IVm)




(IVn)




(IVo)


6. (Original) A compound according to Formulae I' - IV':




(I')



(II')





(III')



(IV')

wherein

A is an indazolyl or benzothiazolyl according to subformulas (a) to (b), respectively,



$R^1$  is H, F, Cl, Br, I, OH, CN, nitro,  $NH_2$ , alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, alkylthio having 1 to 4 carbon atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

$R^2$  is H, alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, or cycloalkylalkyl having 4 to 7 carbon atoms;

$R^3$  is H, F, Cl, Br, I, OH, CN, nitro,  $NH_2$ , alkyl having 1 to 4 carbon atoms, fluorinated alkyl having 1 to 4 carbon atoms, cycloalkyl having 3 to 7 carbon atoms, cycloalkylalkyl having 4 to 7 carbon atoms, alkoxy having 1 to 4 carbon atoms, cycloalkoxy having 3 to 7 carbon atoms, alkylthio having 1 to 4 carbon


atoms, fluorinated alkoxy having 1 to 4 carbon atoms, hydroxyalkyl having 1 to 4 carbon atoms, hydroxyalkoxy having 2 to 4 carbon atoms, monoalkylamino having 1 to 4 carbon atoms, dialkylamino wherein each alkyl group independently has 1 to 4 carbon atoms, Ar or Het;

Ar is an aryl group containing 6 to 10 carbon atoms which is unsubstituted or substituted one or more times by alkyl having 1 to 8 C atoms, alkoxy having 1 to 8 C atoms, halogen, dialkylamino wherein the alkyl portions each have 1 to 8 C atoms, amino, cyano, hydroxyl, nitro, halogenated alkyl having 1 to 8 C atoms, halogenated alkoxy having 1 to 8 C atoms, hydroxyalkyl having 1 to 8 C atoms, hydroxyalkoxy having 2 to 8 C atoms, alkenyloxy having 3 to 8 C atoms, alkylthio having 1 to 8 C atoms, alkylsulphinyl having 1 to 8 C atoms, alkylsulphonyl having 1 to 8 C atoms, monoalkylamino having 1 to 8 C atoms, cycloalkylamino wherein the cycloalkyl group has 3 to 7 C atoms and is optionally substituted, aryloxy wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, arylthio wherein the aryl portion contains 6 to 10 carbon atoms and is optionally substituted, cycloalkyloxy wherein the cycloalkyl group has 3 to 7 C atoms and is optionally substituted, sulfo, sulfonylamino, acylamido, acyloxy or combinations thereof; and


Het is a heterocyclic group, which is fully saturated, partially saturated or fully unsaturated, having 5 to 10 ring atoms in which at least 1 ring atom is a N, O or S atom, which is unsubstituted or substituted one or more times by halogen, aryl having 6 to 10 carbon atoms and is optionally substituted, alkyl having 1 to 8 C atoms, alkoxy having 1 to 8 C atoms, cyano, trifluoromethyl, nitro, oxo, amino, monoalkylamino having 1 to 8 C atoms, dialkylamino wherein each alkyl group has 1 to 8 C atoms, or combinations thereof; or







a pharmaceutically acceptable salt thereof.

7. (Original) A compound according to claim 6, wherein said compound is of formula I'a, Ib, Ie, If, or Ii:




8. (Original) A compound according to claim 6, wherein said compound is of formula II'a to II'i:









9. (Original) A compound according to claim 6, wherein said compound is of formula III'a to III'i:



10. (Original) A compound according to claim 6, wherein said compound is of formula IV'a to IV'i:





11. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 10~~, wherein R<sup>1</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.

12. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 11~~, wherein R<sup>2</sup> is H, methyl, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.

13. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 12~~, wherein R<sup>3</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.

14 (Currently Amended) A compound ~~compound~~ according to claim 1 ~~any one of claims 1 to 13~~, wherein R<sup>1</sup> is H, F, Cl, Br, methyl, methoxy, or amino.

15. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 14~~, wherein R<sup>2</sup> is H or methyl.

16. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 15~~, wherein, and R<sup>3</sup> is H, F, Cl, Br, methyl, methoxy, or amino.

17. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 5~~, wherein R<sup>4</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, phenyl, or methoxy.

18. (Currently Amended) A compound according to claim 1 ~~any one of claims 1 to 5 and 17~~, wherein R<sup>5</sup> is H.

19. (Original) A compound according to claim 17, wherein R<sup>1</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, R<sup>2</sup> is H, methyl, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, and R<sup>3</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.

20. (Original) A compound according to claim 18, wherein R<sup>1</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, R<sup>2</sup> is H, methyl, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl, and R<sup>3</sup> is H, F, Cl, Br, 2-thiophenyl, 3-thiophenyl, 3-furyl, or phenyl.

21. (Original) A compound according to claim 1, wherein said compound is selected from:

N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide hydrochloride,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)benzo[d]isothiazole-3-carboxamide hydrochloride,  
N-(1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,  
N-(1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-3-carboxamide hydrochloride,  
1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
(*R*) 1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
(*S*) 1-Methyl-1H-Indazole-3-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)benzo[d]isothiazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(methoxy)benzo[d]isothiazole-3-carboxamide  
hydroformate,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1H-indazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(cyclopropyl)-1H-indazole-3-carboxamide hydroformate,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1H-indazole-3-carboxamide hydroformate,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1H-indazole-3-carboxamide  
hydroformate,

N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1*H*-indazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)benzo[d]isothiazole-3-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-methoxybenzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(bromo)-1*H*-indazole-3-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(furan-3-yl)-1*H*-indazole-3-carboxamide hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(phenyl)-1*H*-indazole-3-carboxamide hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-2-yl)-1*H*-indazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-5-(thiophen-3-yl)-1*H*-indazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-bromobenzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-cyclopropylbenzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-furan-3-yl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-furan-3-yl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-methoxybenzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,

N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)benzo[d]isothiazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(bromo)-1*H*-indazole-3-carboxamide,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1*H*-indazole-3-carboxamide hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1*H*-indazole-3-carboxamide hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1*H*-indazole-3-carboxamide  
 hydroformate,  
 N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1*H*-indazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-bromobenzo[d]isothiazole-3-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-cyclopropylbenzo[d]isothiazole-3-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(2-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(3-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(4-fluorophenyl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)benzo[d]isothiazole-3-carboxamide  
 hydroformate,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-methoxybenzo[d]isothiazole-3-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(morpholin-4-yl)benzo[d]isothiazole-3-carboxamide

hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-phenylbenzo[d]isothiazole-3-carboxamide hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-3-yl)benzo[d]isothiazole-3-carboxamide  
hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(pyridin-4-yl)benzo[d]isothiazole-3-carboxamide  
hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)benzo[d]isothiazole-3-carboxamide  
hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)benzo[d]isothiazole-3-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(bromo)-1H-indazole-3-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(furan-3-yl)-1H-indazole-3-carboxamide hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(phenyl)-1H-indazole-3-carboxamide hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-2-yl)-1H-indazole-3-carboxamide  
hydroformate,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-6-(thiophen-3-yl)-1H-indazole-3-carboxamide  
hydroformate,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-7-methoxybenzo[d]isothiazole-3-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-7-methoxybenzo[d]isothiazole-3-carboxamide,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-3-ylmethyl)amine,  
N-((3*S*)-1-Aza-bicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-3-ylmethyl)amine,  
N-((3*R*)-1-Aza-bicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide dihydrochloride,  
N-((3*S*)-1-Aza-bicyclo[2.2.2]oct-3-yl)benzothiazole-4-carboxamide dihydrochloride,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-4-carboxamide,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-4-carboxamide,  
N-(1H-Indazol-4-yl)-1-azabicyclo[2.2.2]oct-3-ylcarboxamide,  
N-(1-Azabicyclo[2.2.2]oct-3-yl)-N-(1H-indazol-4-ylmethyl)amine,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-7-carboxamide hydrochloride,  
N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)benzothiazole-7-carboxamide hydrochloride,  
N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide,

N-((3*R*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide hydrochloride,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide,  
 N-((3*S*)-1-Azabicyclo[2.2.2]oct-3-yl)-1H-indazole-7-carboxamide hydrochloride,  
 Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
 (R) Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
 (S) Benzothiazole-4-carboxamide, N-1-aza-bicyclo[2,2,2]oct-3-yl,  
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,  
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,  
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-3-yl,  
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-4-yl,  
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-4-yl,  
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,  
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,  
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, N-1H-indazol-7-yl,  
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,  
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,  
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-4-yl,  
 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,  
 (S) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,  
 (R) 1-Aza-bicyclo[2,2,2]oct-3-ylcarboxamide, benzothiazol-7-yl,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-3-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-3-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-4-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-4-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-5-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,

(R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-6-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-7-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-7-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(1H-indazol-7-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-4-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-4-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-4-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-5-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-5-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-5-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-6-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-6-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-6-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-7-ylmethyl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-7-ylmethyl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-yl)-(benzothiazol-7-ylmethyl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-3-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-3-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-3-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-4-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-4-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-4-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-5-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-5-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-5-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-6-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-6-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-6-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-7-yl)-amine,



(S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-7-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(1H-indazol-7-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-4-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-5-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-6-yl)-amine,  
 (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,  
 (S) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,  
 (R) (1-Aza-bicyclo[2,2,2]oct-3-ylmethyl)-(benzothiazol-7-yl)-amine,  
 and physiological salts thereof.

22. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 1 ~~any one of claims 1 to 21~~ and a pharmaceutically acceptable carrier.

23. (Currently Amended) A method of selectively activating/stimulating  $\alpha$ -7 nicotinic receptors in a mammal wherein such activation/stimulation has a therapeutic effect, comprising administering to an animal in need thereof an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~.

24. (Currently Amended) A method of treating a patient suffering from psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system, and conditions of memory and/or cognition impairment comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~.

25. (Currently Amended) A method of treating a patient suffering from dementia and other conditions with memory loss comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~.

26. (Currently Amended) A method of treating a patient suffering from memory impairment due to mild cognitive impairment due to aging, Alzheimer's disease, schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, Creutzfeld-Jakob disease, depression, aging, head trauma, stroke, CNS hypoxia, cerebral senility, or multiinfarct dementia comprising administering an effective amount of a compound according according to claim 1 ~~any one of claims 1 to 21~~.

27. (Currently Amended) A method of treating and/or preventing dementia in an Alzheimer's patient comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~ to inhibit the binding of an amyloid beta peptide with nAChRs.

28. (Currently Amended) A method of treating a patient for alcohol withdrawal or treating a patient with anti-intoxication therapy comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~.

29. (Currently Amended) A method of treating a patient to provide for neuroprotection against damage associated with strokes and ischemia and glutamate-induced excitotoxicity comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21~~.

30. (Currently Amended) A method of treating a patient suffering from nicotine addiction, pain, jetlag, obesity and/or diabetes, or a method of inducing smoking cessation in a patient comprising administering to the patient an effective amount of a compound according to

claim 1 ~~any one of claims 1 to 21.~~

31. (Currently Amended) A method of treating a patient suffering from mild cognitive impairment (MCI), vascular dementia (VaD), age-associated cognitive decline (AACD), amnesia associated with open-heart-surgery, cardiac arrest, general anesthesia, memory deficits from exposure to anesthetic agents, sleep deprivation induced cognitive impairment, chronic fatigue syndrome, narcolepsy, AIDS-related dementia, epilepsy-related cognitive impairment, Down's syndrome, Alcoholism related dementia, drug/substance induced memory impairments, Dementia Puglistica (Boxer Syndrome), or animal dementia comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21.~~

32. (Currently Amended) A method of treating a patient suffering from a disease state involving decreased nicotinic acetylcholine receptor activity comprising administering to the patient an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21.~~

33. (Currently Amended) A method for the treatment or prophylaxis of a disease or condition resulting from dysfunction of nicotinic acetylcholine receptor transmission in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21.~~

34. (Currently Amended) A method for the treatment or prophylaxis of a disease or condition resulting from defective or malfunctioning nicotinic acetylcholine receptors in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21.~~

35. (Currently Amended) A method for the treatment or prophylaxis of a disease or condition resulting from suppressed nicotinic acetylcholine receptor transmission in a mammal comprising administering to the mammal an effective amount of a compound according to claim

1 ~~any one of claims 1 to 21.~~

36. (Currently Amended) A method for the treatment or prophylaxis of a disease or condition resulting from loss of cholinergic synapses in a mammal comprising administering to the mammal an effective amount of a compound according to claim 1 ~~any one of claims 1 to 21.~~